FOXP3 and cancer: AZD8701, a first-in-class human clinical candidate antisense oligonucleotide (ASO) inhibitor targeting Foxp3, is currently being evaluated in Phase 1a/b clinical trials (NCT04504669) for its potential use in cancer treatment (96).